Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.

Cetin M, Uçar O, Cicekçioğlu H, Güven Cetin Z, Sahin M, Vasfi Ulusoy F, Aydoğdu S.

Acta Cardiol. 2012 Jun;67(3):317-23.

2.

Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.

Işık S, Cetin M, Ciçekçioğlu H, Uçar O, Çetin ZG, Ozuğuz U, Bakır F, Berker D, Güler S.

Anadolu Kardiyol Derg. 2011 Sep;11(6):523-9. doi: 10.5152/akd.2011.137. Epub 2011 Aug 8.

3.

Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.

Duman D, Palit F, Simsek E, Bilgehan K, Sacide A.

Can J Cardiol. 2009 Oct;25(10):e353-6.

4.

Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.

Farmakis D, Parissis JT, Bistola V, Paraskevaidis IA, Iliodromitis EK, Filippatos G, Kremastinos DT.

Int J Cardiol. 2010 Feb 18;139(1):75-9. doi: 10.1016/j.ijcard.2008.10.003. Epub 2008 Oct 30.

PMID:
18973957
5.

Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.

Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos DT.

Am J Cardiol. 2005 Aug 1;96(3):423-6.

PMID:
16054474
6.

Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.

Lunghetti S, Palmerini E, Urselli R, Maffei S, Guarino E, Focardi M, Mondillo S, Favilli R.

Cardiol J. 2011;18(5):532-7.

7.

Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.

Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, Zhou Y, Shang DY.

Cardiovasc Ther. 2013 Apr;31(2):108-14. doi: 10.1111/1755-5922.12001.

PMID:
23490237
8.

Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.

Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.

Am J Cardiol. 2006 Jul 1;98(1):102-6. Epub 2006 May 6.

PMID:
16784930
9.
10.

Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.

Kurt IH, Yavuzer K, Batur MK.

Heart Vessels. 2010 Sep;25(5):392-9. doi: 10.1007/s00380-009-1216-4. Epub 2010 Jul 31.

PMID:
20676961
11.

Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.

Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT.

Heart. 2006 Dec;92(12):1768-72. Erratum in: Heart. 2009 Jan;95(1):84.

12.

Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.

Paraskevaidis IA, Bistola V, Ikonomidis I, Parissis JT, Papadopoulos C, Filippatos G, Kremastinos DT.

Am J Cardiol. 2008 Nov 1;102(9):1225-9. doi: 10.1016/j.amjcard.2008.06.060. Epub 2008 Sep 4.

PMID:
18940297
13.

Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.

Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO.

Heart Lung Circ. 2008 Jun;17(3):206-10. doi: 10.1016/j.hlc.2007.10.014. Epub 2008 Jan 31.

PMID:
18242130
14.

Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.

Duygu H, Turk U, Ozdogan O, Akyuz S, Kirilmaz B, Alioglu E, Gunduz R, Bozkaya YT, Turkoglu C, Payzin S.

Cardiovasc Ther. 2008 Fall;26(3):182-8. doi: 10.1111/j.1755-5922.2008.00050.x.

PMID:
18786088
15.

Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.

Büyüklü M, Kürüm AT, Tatlý E, Set T.

Arq Bras Cardiol. 2012 Jul;99(1):659-64. Epub 2012 Jun 26. English, Portuguese.

16.
17.

Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?

Palmerini E, Söderberg S, Mondillo S, Favilli R, Lunghetti S.

Acute Card Care. 2015 Mar;17(1):14-9. doi: 10.3109/17482941.2015.1005102. Epub 2015 Mar 25.

PMID:
25806830
18.

Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.

Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M.

Eur J Heart Fail. 2007 Jan;9(1):75-82. Epub 2006 Jul 7.

19.

The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.

Celik T, Iyisoy A, Yuksel UC, Kardesoglu E.

Int J Cardiol. 2008 Aug 1;128(1):97-9; authr reply 100-2. doi: 10.1016/j.ijcard.2008.01.022. Epub 2008 May 22.

PMID:
18501448
20.

Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.

Branzi G, Malfatto G, Villani A, Ciambellotti F, Revera M, Giglio A, Rosa FD, Facchini M, Parati G.

J Cardiovasc Med (Hagerstown). 2010 Sep;11(9):662-8. doi: 10.2459/JCM.0b013e32833832f6.

PMID:
20613551
Items per page

Supplemental Content

Write to the Help Desk